Specialty Overview

Best Hospitals for Lung Cancer Treatment in Hyderabad, India

4 surgical oncology hospitals in our India network are listed in Hyderabad, accredited by JCI, NABH, with 10,076 beds combined.

4
Hospitals Listed
1
City
4.5
Avg. Rating
2
Accreditation Types
The Short Answer

This page lists the surgical oncology hospitals in our directory offering Lung Cancer Treatment in Hyderabad, India, including KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills. Each listing links through to the hospital's full profile page.

Ask us about lung cancer treatment in Hyderabad, India

Share a few details and our care coordination team will get back to you with next steps.

Compare 4 accredited hospitals for Surgical Oncology in Hyderabad, India

Starting from$1,000

🇮🇳 KIMS Hospitals, Secunderabad

Hyderabad, India 4.8 (743 reviews) 8,300 beds
Why consider this hospital?
4.8/5 rating from 743 reviewsAccredited by JCI, NABH8,300 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsNephrology
Accredited by JCI, NABH

Patients considering lung cancer treatment can be cared for by KIMS Hospitals, Secunderabad's care team in Hyderabad, India, from initial consultation through recovery. KIMS Hospitals, Secunderabad, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.8/5
Rating
2000
Established
8,300
Beds
Hyderabad, India
Location
Yashoda Hospitals, Secunderabad
Starting from$1,000

🇮🇳 Yashoda Hospitals, Secunderabad

Secunderabad, Hyderabad, India 4.7 (518 reviews) 1,026 beds
Why consider this hospital?
4.7/5 rating from 518 reviewsAccredited by NABH1,026 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyNeurologyOrthopedicsOncologyGastroenterology
Accredited by NABH

Patients considering lung cancer treatment can be cared for by Yashoda Hospitals, Secunderabad's care team in Secunderabad, Hyderabad, India, from initial consultation through recovery. Yashoda Hospitals, Secunderabad, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.7/5
Rating
1989
Established
1,026
Beds
Secunderabad, Hyderabad, India
Location
Apollo Hospital DRDO
Starting from$1,000

🇮🇳 Apollo Hospital DRDO

Kanchan Bagh, Hyderabad, India 4.5 (82 reviews) 200 beds
Why consider this hospital?
4.5/5 rating from 82 reviewsAccredited by NABH, JCI200 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsOncologyNeurosciencesTransplant
Accredited by NABH, JCI

Patients considering lung cancer treatment can be cared for by Apollo Hospital DRDO's care team in Kanchan Bagh, Hyderabad, India, from initial consultation through recovery. Apollo Hospital DRDO, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.5/5
Rating
2001
Established
200
Beds
Kanchan Bagh, Hyderabad, India
Location
Apollo Hospitals, Jubilee Hills
Starting from$1,000

🇮🇳 Apollo Hospitals, Jubilee Hills

Hyderabad, India 4.1 (44 reviews) 550 beds
Why consider this hospital?
4.1/5 rating from 44 reviewsAccredited by JCI, NABH550 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering lung cancer treatment can be cared for by Apollo Hospitals, Jubilee Hills's care team in Hyderabad, India, from initial consultation through recovery. Apollo Hospitals, Jubilee Hills, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.1/5
Rating
1988
Established
550
Beds
Hyderabad, India
Location
Our Methodology

How we selected these hospitals

A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Hyderabad, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Lung Cancer Treatment in Hyderabad, India?

Choosing the right hospital for lung cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include surgical oncology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Lung Cancer Treatment

Lung cancer treatment encompasses a multidisciplinary spectrum of interventions — including anatomic resection, stereotactic body radiotherapy (SBRT), platinum-doublet chemotherapy, targeted molecular therapy (EGFR, ALK, ROS1 inhibitors), and immune checkpoint immunotherapy — tailored to histological subtype, stage, and genomic profile.

5–14 days (varies by modality: 5–7 days for VATS/robotic lobectomy; up to 14 days for open pneumonectomy or complex chemo-induction cases)
Hospital Stay
3–6 weeks (3 weeks post VATS/robotic resection or SBRT completion; 5–6 weeks post open thoracotomy or pneumonectomy; ongoing systemic therapy patients travel only after oncologist clearance and confirmed DVT prophylaxis plan)
Total Stay in Country (Fit-to-Fly)
70–90% 5-year survival (Stage I NSCLC with curative resection or SBRT); 40–65% objective response rate (Stage III–IV with targeted therapy or immunotherapy)
Success Rate

Clinical Overview

  • Lung cancer is a malignancy arising from the bronchial epithelium or alveolar parenchyma and is broadly classified into non-small cell lung cancer (NSCLC — comprising adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma, accounting for ~85% of cases) and small cell lung cancer (SCLC, ~15% of cases).
  • NSCLC staging follows the TNM 9th Edition system (IASLC 2024), with Stage I–II disease amenable to curative-intent surgery or definitive radiotherapy, Stage III disease managed with concurrent chemoradiotherapy ± consolidation immunotherapy (e.g., durvalumab per the PACIFIC trial), and Stage IV disease approached with systemic therapy guided by comprehensive biomarker profiling.
  • SCLC is staged as limited-stage (LS-SCLC) or extensive-stage (ES-SCLC), with concurrent chemoradiation for LS-SCLC and platinum-etoposide plus atezolizumab or durvalumab for ES-SCLC.
Full details →

Who is a Candidate?

  • ELIGIBLE PATIENTS:
  • Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage seeking curative, consolidation, or palliative systemic/local therapy
  • Stage I–II NSCLC patients medically fit for anatomic pulmonary resection (lobectomy, segmentectomy) or SBRT — assessed by pulmonary function testing (FEV1 >40% predicted post-resection, DLCO >40%)
  • Stage III NSCLC patients eligible for concurrent chemoradiotherapy (PS ECOG 0–1, adequate cardiopulmonary reserve)
  • +25 more

Treatment Options & Approaches

  • SURGICAL APPROACHES:

Recovery

  • PHASE 1 — PRE-ARRIVAL PLANNING (2–4 Weeks Before Travel):

Risks to be aware of

  • Lung cancer treatment carries procedure- and modality-specific risks that patients must understand prior to consent.
  • For surgical resection (VATS/Robotic Lobectomy), risks include prolonged air leak (>5 days, occurring in 8–15% of cases), atrial fibrillation (15–20% post-lobectomy, most self-limiting), pneumonia (3–5%), bronchopleural fistula (<1% but potentially life-threatening), and in-hospital mortality of approximately 1–2% for lobectomy and 5–8% for pneumonectomy.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides comprehensive end-to-end non-medical coordination that begins the moment a patient enquires and continues through post-departure remote follow-up.

Cost Range for Related Procedures

Cancer Surgery$4,000$15,000
Chemotherapy$1,000$4,000
Radiation Therapy$3,500$10,000
Get a personalised estimate with our cost calculator →

Common questions about Lung Cancer Treatment

What is the cost of lung cancer treatment in India compared to the UAE?
The cost of lung cancer treatment varies by modality and stage. In India, a VATS lobectomy (surgery alone, including hospital stay, anaesthesia, and standard medications) typically costs USD 6,000–12,000. A course of SBRT runs USD 4,000–8,000. A complete concurrent chemoradiotherapy programme (6–7 weeks) costs USD 8,000–18,000. First-line systemic therapy initiation (targeted agents or immunotherapy, per cycle) costs USD 1,500–5,000 per cycle depending on the drug. In the UAE (Dubai/Abu Dhabi), equivalent procedures cost approximately 60–100% more: VATS lobectomy USD 18,000–35,000; SBRT USD 15,000–28,000; concurrent CRT USD 22,000–55,000; and systemic therapy initiation USD 5,000–15,000 per cycle. Both destinations provide JCI-accredited hospitals, internationally trained thoracic oncologists, NGS-guided molecular profiling, and robotic surgical platforms. India offers the lowest cost globally for equivalent clinical quality, while the UAE offers premium private hospital environments and superior geographic convenience for patients from the GCC, East Africa, and the broader Arab world. GAF Healthcare provides a personalised itemised cost estimate within 48 hours of receiving your medical records, with no obligation to proceed.
How long do I need to stay in the country before I am fit to fly home after lung cancer treatment?
Fit-to-fly timelines are modality-specific and are determined by your thoracic surgeon or oncologist at the treating centre. After VATS or robotic-assisted lobectomy or segmentectomy, most patients are cleared for international flight at 3 weeks post-surgery, provided chest X-ray confirms no residual pneumothorax, pain is controlled on oral analgesia, and there are no signs of DVT on clinical assessment. Long-haul flights carry an elevated risk of deep vein thrombosis (DVT) and pulmonary embolism after thoracic surgery; all surgical patients receive a prescription for low molecular weight heparin (LMWH) and compression stockings for the return journey. After open thoracotomy or pneumonectomy, the fit-to-fly timeline is extended to 5–6 weeks, contingent on wound healing, stable spirometry, and cardiologist clearance. After SBRT, patients are typically cleared to fly 2–3 weeks after the final fraction once acute radiation reactions have settled. After the first cycle of chemotherapy, patients must wait until bone marrow nadir recovery — usually Day 14–21 — with white blood cell count above 3.0 × 10⁹/L and platelets above 100 × 10⁹/L before long-haul travel. Patients on oral targeted therapy (e.g., osimertinib, alectinib) may travel once tolerating the medication without significant side effects, typically 2–3 weeks after initiation. GAF Healthcare issues a formal fit-to-fly certificate from the treating physician, which is accepted by airlines for boarding with medical documentation.
What is the success rate of lung cancer treatment?
Success rates in lung cancer are stage- and modality-dependent and are best understood by specific disease scenario. For Stage I NSCLC treated with curative-intent VATS or robotic lobectomy, the 5-year overall survival rate is 70–90% (Stage IA3: 77–90%; Stage IB: 68–75% per IASLC data). SBRT for medically inoperable Stage I NSCLC achieves local control rates of 85–95% at 3 years, with 5-year overall survival of 40–60% (reflecting co-morbidities rather than oncological failure). For Stage II NSCLC with surgery ± adjuvant chemotherapy or osimertinib (ADAURA trial for EGFR-mutant disease, 88% DFS at 4 years), 5-year survival is 53–65%. For Stage III NSCLC managed with concurrent chemoradiotherapy plus durvalumab consolidation (PACIFIC regimen), median overall survival exceeds 47 months with a 5-year OS rate of approximately 42%. For Stage IV EGFR-mutant NSCLC treated with osimertinib, median progression-free survival is 18–25 months and median overall survival exceeds 38 months per the FLAURA data. For Stage IV ALK-rearranged NSCLC on alectinib, median PFS is 34 months. For high PD-L1 expressors (TPS ≥50%) on pembrolizumab monotherapy, 5-year OS rates of 31% have been reported in the KEYNOTE-024 trial — a remarkable benchmark for Stage IV disease. SCLC limited-stage achieves 5-year OS of 20–35% with concurrent chemoradiotherapy; extensive-stage SCLC median OS is 12–13 months with modern chemoimmunotherapy. GAF Healthcare's partner centres treat high volumes of thoracic oncology cases and submit outcomes data to international tumour registries, ensuring transparency and accountability.

How GAF Healthcare Assists in Choosing the Best Hospital for Lung Cancer Treatment in Hyderabad, India

Discover the Top Hospitals for Lung Cancer Treatment in Hyderabad, India

This page lists 4 accredited surgical oncology hospitals in Hyderabad, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about lung cancer treatment in Hyderabad, India

How many surgical oncology hospitals are listed in Hyderabad, India?
4 hospitals in our Hyderabad, India directory are currently listed for surgical oncology including Lung Cancer Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Hyderabad, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there surgical oncology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for lung cancer treatment?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about lung cancer treatment in Hyderabad, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for lung cancer treatment in Hyderabad, India.

Contact us to report an inaccuracy on this page.